Back to Library
Weight LossMetabolic Health

Cagrilintide + Retatrutide

The 'Ultimate' Stack: Amylin Satiety + Triple Agonist Metabolism.

Overview

This blend represents the pinnacle of current obesity research, combining the 'Triple Agonist' power of Retatrutide (GIP/GLP-1/Glucagon) with the 'Mechanical Satiety' of Cagrilintide (Amylin). While Retatrutide dramatically increases metabolic rate and liver fat clearing, Cagrilintide provides a physical 'gastric brake' that stops food intake. Together, they are theorized to produce weight loss exceeding 25-30%, rivaling or beating bariatric surgery.

Chemical Information

IUPAC Name
Retatrutide + Acylated Amylin Analogue
Sequence
Blend of Two Peptides
Molecular Mass
Mixture (N/A)
Formula
Mixture (N/A)
Chemical Structure not available

Mechanism of Action

Functions as a Quadruple-Pathway Synergist. 1. Retatrutide (GIP/GLP-1/Glucagon): Fires on all metabolic cylinders—burning fat (Glucagon), sensitizing insulin (GIP), and reducing appetite (GLP-1). 2. Cagrilintide (Amylin): Acts as the 'anchor.' Even if the metabolic fire is high, Amylin physically prevents overeating by locking the gastric emptying rate and signaling deep satiety to the hindbrain. Synergy: This combination addresses the limitation of Retatrutide (where appetite suppression might not match its fat-burning power) by adding the strongest known satiety agent.

Potential Research Fields

Morbid ObesityMetabolic SyndromeLiver FibrosisBariatric Mimicry

Recent Research

This blend is considered the 'frontier' of medical weight loss. By stacking the most powerful metabolic agent ever discovered (Retatrutide) with the most potent satiety agent (Cagrilintide), researchers aim to break the '30% barrier' of weight loss. While Retatrutide accelerates calorie burning via glucagon, Cagrilintide ensures the patient physically cannot consume enough calories to counteract it. It is currently being explored as a direct pharmaceutical alternative to gastric bypass surgery.

Bibliography / Scientific References

Related Peptides

Research
SLU-PP-332

Exercise mimetic for mitochondrial biogenesis and fat loss

Research
5-Amino-1MQ

NNMT inhibitor for fat loss and NAD+ restoration

Peptide Information Guide
Administration Type
Injectable (Subcutaneous)

Injectable administration protocol for research.

Vial Strength
10mg
Reconstitution
Reconstitute with 2ml Physiological Solution (Saline)
Dosage Options
20 Units
1x Week
Protocol for 10mg/2ml blend. (Conc: 5mg/ml. 20 units = 0.2ml = 1 mg total blend). Adjust as directed.
Schedule
1x Per Week
Timing: One specific day.
Duration
According to the Doctor
Potential Side Effects
Nausea
highvery common
Fatigue
moderatecommon (rapid weight loss)
Heart Rate Increase
lowcommon
Research Use Only

This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.